Androgen News and Research

RSS

Scientists discover how androgen plays a role in the development of prostate cancer

Scientists have discovered for the first time a specific biochemical pathway by which the sex hormone, androgen, increases levels of harmful chemicals called reactive oxygen species (ROS) in the prostate gland that play a role in the development of prostate cancer.

8 Nov 2006

New research could affect future treatment options for prostate cancer

Two new studies on the treatment of prostate cancer could well affect future treatment options for patients.

8 Nov 2006

Overweight women more likely to have polycystic ovary syndrome

Overweight and obese Spanish women appear five times as likely as lean women to have polycystic ovary syndrome, a condition that decreases fertility and contributes to other illnesses, according to an article in the October 23 issue of Archives of Internal Medicine.

23 Oct 2006

Long-term oncologic outcomes: A 40 year radical prostatectomy single institution series

Single institution long-term outcomes for radical prostatectomy are scarce in the literature. In the August 2006 issue of the Journal of Urology, Dr. Porter from the Virginia Mason Medical Center, Seattle, WA reports on 25-year cancer outcomes for radical prostatectomy (RP).

6 Sep 2006

Bone protection by estrens occurs through non-tissue-selective activation of the androgen receptor

A new study appearing in the September issue of the Journal of Clinical Investigation indicates that caution might be needed if a new group of drugs known as estrens are to be developed for the treatment of osteoporosis.

4 Sep 2006

Women's Health Network petitions FDA to halt sales of estrogen, testosterone combination treatments

The National Women's Health Network has petitioned FDA to stop sales of Solvay's Estratest and Breckenridge Pharmaceuticals' Syntest, which are estrogen-testosterone combination therapies used to treat menopause-associated hot flashes, until they are proven safe and effective, Reuters reports.

24 Aug 2006

Variances in patterns of care for patients with prostate cancer failing primary therapy

Variables that impact management of failed primary therapy for prostate cancer (CaP) are not well defined.

21 Aug 2006

Intermittent androgen deprivation in biochemical recurrence of prostate cancer after radiotherapy

Intermittent androgen deprivation (IAD) is commonly used in the treatment of CaP, which theoretically may delay the development of hormone resistance.

17 Aug 2006

When a patient is diagnosed with prostate cancer, what determines whether he will receive early androgen ablation?

While the benefits of androgen ablation therapy have been well documented in patients with locally advanced and metastatic prostate cancer, there is a paucity of evidence its role in patients with low-grade, low-stage disease.

16 Aug 2006

Biomira Stimuvax prostate cancer study results published

Biomira Inc. has announced publication of study results showing that Stimuvax, formerly known as BLP25 Liposome Vaccine or L-BLP25, could slow rising Prostate Specific Antigen (PSA) levels in some post-surgical prostate cancer patients

20 Jul 2006

Intermittent androgen deprivation in biochemical recurrence of prostate cancer after radiotherapy

Intermittent androgen deprivation (IAD) is commonly used in the treatment of CaP, which theoretically may delay the development of hormone resistance.

29 Jun 2006

Obesity associated with less favorable outcome after radiation therapy for prostate cancer

Obese men with prostate cancer are at higher risk for treatment failure after primary radiation therapy, according to a new study.

27 Jun 2006

Few well performed studies address management of lymph node positive prostate cancer

Dr. Gregory Swanson and associates from the University of Texas, San Antonio Health Science Center reviews the data for various treatment options in patients with lymph node positive prostate cancer (CaP).

27 Jun 2006

Advanced prostate cancer can be treated successfully with intermittent chemotherapy

Advanced prostate cancer can be treated successfully with intermittent chemotherapy, according to a study conducted by Oregon Health & Science University Cancer Institute scientists.

6 Jun 2006

Monitoring anemia provides clues to prostate cancer treatment response

Researchers from the Oregon Health & Science University Cancer Institute and Southwest Oncology Group have identified a new method of determining how men with advanced prostate cancer will respond to treatment.

1 Jun 2006

Novel protein JHDM2A offers new look at male hormone regulation

For the second time in less than a year, University of North Carolina at Chapel Hill scientists have purified a novel protein and have shown it can alter gene activity by reversing a molecular modification previously thought permanent.

8 May 2006

A contraceptive pill for men!

According to a Sydney scientist a hormone-based contraceptive for men has the ability to reverse its effect just four months after stopping its use.

1 May 2006

Novel and important benefits of vitamin D and the problems associated with vitamin D deficiency

...will be discussed at the American Association of Clinical Endocrinologists (AACE) Fifteenth Annual Meeting and Clinical Congress, April 26-30, at the Hyatt Regency Chicago.

19 Apr 2006

Prostate cancer research may be faster with prostate-specific antigen endpoints

A new study from Columbia University Medical Center researchers at NewYork-Presbyterian Hospital/Columbia, who are members of the Southwest Oncology Group (SWOG), suggests that certain changes in prostate-specific antigen (PSA) levels may serve as surrogate endpoints for prostate cancer survival.

18 Apr 2006

Usage and outcomes of primary androgen deprivation therapy for localized prostate cancer

In the online March 2006 version of Cancer, Dr. Kawakami and associates report from the CaPSURE database that primary androgen deprivation therapy (PADT) is used in 14% of prostate cancer (CaP) patients with reasonable outcomes at approximately 5 years follow-up.

11 Apr 2006

Androgen News and Research

Scientists discover how androgen plays a role in the development of prostate cancer

New research could affect future treatment options for prostate cancer

Overweight women more likely to have polycystic ovary syndrome

Long-term oncologic outcomes: A 40 year radical prostatectomy single institution series

Bone protection by estrens occurs through non-tissue-selective activation of the androgen receptor

Women's Health Network petitions FDA to halt sales of estrogen, testosterone combination treatments

Variances in patterns of care for patients with prostate cancer failing primary therapy

Intermittent androgen deprivation in biochemical recurrence of prostate cancer after radiotherapy

When a patient is diagnosed with prostate cancer, what determines whether he will receive early androgen ablation?

Biomira Stimuvax prostate cancer study results published

Intermittent androgen deprivation in biochemical recurrence of prostate cancer after radiotherapy

Obesity associated with less favorable outcome after radiation therapy for prostate cancer

Few well performed studies address management of lymph node positive prostate cancer

Advanced prostate cancer can be treated successfully with intermittent chemotherapy

Monitoring anemia provides clues to prostate cancer treatment response

Novel protein JHDM2A offers new look at male hormone regulation

A contraceptive pill for men!

Novel and important benefits of vitamin D and the problems associated with vitamin D deficiency

Prostate cancer research may be faster with prostate-specific antigen endpoints

Usage and outcomes of primary androgen deprivation therapy for localized prostate cancer

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News